Autor: |
Alonso-Sardón M; Department of Biomedical and Diagnostic Sciences, School of Medicine, University of Salamanca, 37008 Salamanca, Spain., Sáez-Lorenzo M; Pharmacological Treatments in Persons with Disabilities, School of Medicine, University of Salamanca, 37008 Salamanca, Spain., Chamorro AJ; Disability and Prevalent Chronic Diseases, Adjunct of Internal Medicine, Faculty of Medicine, University Hospital of Salamanca (SACYL), 37008 Salamanca, Spain., Fernández-Martín LC; Expert in Social and Communication Skills in Persons with Disabilities, School of Phicology, University of Salamanca, 37008 Salamanca, Spain., Iglesias-de-Sena H; Pharmacological Treatments in Persons with Disabilities, School of Medicine, University of Salamanca, 37008 Salamanca, Spain., González-Núñez V; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37008 Salamanca, Spain.; Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca, 37008 Salamanca, Spain., Santos-Sánchez JÁ; Specialist in Traumatology and Radiodiagnosis in Persons with Disabilities, School of Medicine, University of Salamanca, 37008 Salamanca, Spain., Carbonell C; Specialist in Infectious Diseases, Salamanca University Hospital, 37007 Salamanca, Spain., Lorenzo-Gómez MF; Disability and Incontinence, Faculty of Medicine, University of Salamanca Clinical Hospital (SACYL), 37007 Salamanca, Spain., Mirón-Canelo JA; Preventive Medicine and Public Health, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. |
Abstrakt: |
(1) Background: Providing the patient with the health care they need in a personalized and appropriate manner and without adverse effects (AEs) is a part of quality of care and patient safety. The aim of this applied research project was the assessment of AEs as a clinical risk in patients with high social vulnerability such as persons with intellectual and developmental disabilities (PwIDD). (2) Methods: A retrospective epidemiological cohort study was performed on exposed and unexposed groups (the control group) in order to estimate the incidence of AEs in PwIDDs and assess their importance for this category of patients. (3) Results: AEs were observed with a frequency of 30.4% (95% CI) in the PwIDD exposed group, with significant differences to the unexposed group ( p = 0.009). No differences were observed with regards to gender. Age was as a marker of care risk, with the highest incidence of AEs in the group of 60-69 years. (4) Conclusions: PwIDDs have a high risk of suffering AEs while receiving health care assistance due to their high social and clinical vulnerability. Health care practitioners must therefore be aware of these results and keep these observations in mind in order to carry out personalized, preventive, competent, effective, and safe medical care. |